Evidence map›Paper›PMID 35410222›Full record

ArticleOrphanet journal of rare diseases2022

Designing rare disease care pathways in the Republic of Ireland: a co-operative model.

A J Ward, D Murphy, R Marron, V McGrath, M Bolz-Johnson, W Cullen, A Daly, O Hardiman, A Lawlor, S A Lynch and 7 more

Open access · goldAbstract read
In one paragraph

Article in Orphanet journal of rare diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Nurses' Knowledge of Rare Diseases: A Systematic Review.Nursing reports (Pavia, Italy) · 2025
    Review
  6. Nursing's Role in Advancing Care for Rare Genetic Diseases.The Nursing clinics of North America · 2025
    Review
  7. Article
  8. Article
  9. Strengthening health systems for access to gene therapy in rare genetic disorders.Molecular therapy. Methods & clinical development · 2024
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

A J WardNational Rare Diseases Office, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland.
D MurphyNational Rare Diseases Office, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland.
R MarronNational Rare Diseases Office, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland.
V McGrathRare Diseases Ireland, Carmichael House, North Brunswick St, Dublin 7, Ireland.
M Bolz-JohnsonEuropean Organisation for Rare Diseases (EURORDIS), Paris, France.
W CullenDivision of Urban General Practice, School of Medicine, University College, Dublin, Ireland.
A DalyEuropean Organisation for Rare Diseases (EURORDIS), Paris, France.
O HardimanAcademic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland.
A Lawlor22Q11 Ireland, North Brunswick Street, Dublin, Ireland.
S A LynchClinical Genetics, Children's Health Ireland (CHI) at Crumlin, Dublin, Ireland.
M MacLachlanDisability Services, Health Service Executive, Dublin, Ireland.
J McBrienDepartment of General Paediatrics and Neurodisability, CHI at Temple Street, Dublin, Ireland.
S Ni BhriainOffice of the National Lead for Integrated Care, Health Service Executive, Dr. Steeven's Hospital, Dublin, Ireland.
J J O'ByrneSchool of Medicine, University College Dublin, Dublin, Ireland.
S M O'ConnellDepartment of Diabetes and Endocrinology, Children's Health Ireland (CHI) at Crumlin, Dublin, Ireland.
J TurnerNational Rare Diseases Office, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland.
E P TreacyNational Rare Diseases Office, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland. etreacy@mater.ie.ORCID 0000-0002-6226-1615
Mater Misericordiae University Hospital · IEUniversity College Dublin · IEEuropean Organisation for Rare Diseases · FR22q11 Ireland · IEHealth Service Executive · IENational University of Ireland, Maynooth · IERoyal College of Surgeons in Ireland · IETrinity College Dublin · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRare diseases (RDs) are often complex, serious, chronic and multi-systemic conditions, associated with physical, sensory and intellectual disability. Patients require follow-up management from multiple medical specialists and health and social care professionals involving a high level of integrated care, service coordination and specified care pathways. METHODS AND

objectivesThis pilot study aimed to explore the best approach for developing national RD care pathways in the Irish healthcare system in the context of a lack of agreed methodology. Irish clinical specialists and patient/lived experience experts were asked to map existing practice against evidence-based clinical practice guidelines (CPGs) and best practice recommendations from the European Reference Networks (ERNs) to develop optimal care pathways. The study focused on the more prevalent, multisystemic rare conditions that require multidisciplinary care, services, supports and therapeutic interventions.

results29 rare conditions were selected across 18 ERNs, for care pathway development. Multidisciplinary input from multiple specialisms was relevant for all pathways. A high level of engagement was experienced from clinical leads and patient organisations. CPGs were identified for 26 of the conditions. Nurse specialist, Psychology, Medical Social Work and Database Manager roles were deemed essential for all care pathways. Access to the therapeutic Health Service Professionals: Physiotherapy, Occupational Therapy, and Speech and Language Therapy were seen as key requirements for holistic care. Genetic counselling was highlighted as a core discipline in 27 pathways demonstrating the importance of access to Clinical Genetics services for many people with RDs.

conclusionsThis study proposes a methodology for Irish RD care pathway development, in collaboration with patient/service user advocates. Common RD patient needs and health care professional interventions across all pathways were identified. Key RD stakeholders have endorsed this national care pathway initiative. Future research focused on the implementation of such care pathways is a priority.

Indexed as

Critical PathwaysRare DiseasesDelivery of Health CareHumansIrelandPilot ProjectsCare pathwaysIrelandRare diseases

Identifiers

PMID35410222
PMCPMC8996209
OpenAlexW4225569560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.